Quantcast

BCC Research Publishes a New Report on Global Markets for Cervical Cancer Drugs and Diagnostics

September 20, 2013

The global market for cervical cancer drugs and diagnostics was valued at $11.3 billion in 2012 and is expected to reach $11.6 billion by 2013. BCC Research projects the market to reach nearly $15.6 billion by 2018, and register a compound annual growth rate (CAGR) of 6.1%.

Wellesley, MA (PRWEB) September 20, 2013

According to a new technical market research report, Therapies and Diagnostics for Cervical Cancer from BCC Research (http://www.bccresearch.com), the global market for cervical cancer drugs and diagnostics was valued at $11.3 billion in 2012 and is expected to reach $11.6 billion by 2013. BCC Research projects the market to reach nearly $15.6 billion by 2018, and register a compound annual growth rate (CAGR) of 6.1%.

According to the World Health Organization (WHO), cervical cancer ranks as the third and the fourth most common cause of cancer incidence and mortality in women worldwide. While cervical cancer mortality rate has decreased in the past few years due to early detection and intervention; over-diagnosis and over-treatment of the disease continue to remain as critical problems, leading to unnecessary anxiety, pain, expense, and inconvenience. With more than half a million new cases and 275,000 deaths each year, cervical cancer is one of the cancers that continue to be a major public health problem.

Cervical cancer can occur at a relatively young age compared with other major cancers. Studies have clearly shown that cervical cancer primarily affects young adult women who are actively involved in their careers or caring for their families. Wide variations in incidence of cervical cancer exist between high-burden and low-burden countries. These contrasts are believed to reflect both differences in exposure to risk factors and protection from screening. Sexually transmitted infection with high-risk human papillomavirus (HPV) types is the main etiological factor for cervical cancer. In addition, increased frequency of smoking, use of oral contraception, and certain sexually transmittable infections can also be attributed to the recent rise in cervical cancer incidence among young cohorts.

This comprehensive report from BCC Research provides an overview of the current and potential global market for cervical cancer, including treatments and screening and testing technologies. It also identifies and analyzes the key trends driving the global cervical cancer therapeutics market. The study’s focus is on cervical disorders, current treatment strategies and drugs, chemotherapy, and other treatment modalities and testing and screening methods. This BCC Research report covers the important trends in the field, research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2018. In addition, this report examines the treatment usage patterns in the global cervical cancer therapeutics market, the competitive landscape and emerging players, and the pipeline products as well as opportunities for future players. This report aims to increase the awareness of current and emerging drugs and technologies for cervical cancers, including prophylactics, therapeutics, chemotherapy, and surgical therapy.

This new report from BCC Research is the result of an exhaustive literature search on cervical cancer and disorders; products; global incidence; and drug developments. Secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications.

This report will be of interest largely to those in the pharmaceutical and biotechnology industries, as well as clinics, hospitals, and research institutes. This report will also prove crucial for investment firms in the concerned sector.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11136040.htm


Source: prweb



comments powered by Disqus